"The NCCN NSCLC Guidelines Panel strongly endorses broader molecular profiling with the goal of identifying rare driver mutations for which effective drugs may already be available, or to appropriately counsel patients regarding the availability of clinical trials. Broad molecular profiling is a key component of the improvement of care of patients with NSCLC"
Now on to the recent scientific articles related to FoundationOne and/or FoundationOne Heme:
Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma
Capelleti et al. Clinical Cancer Research.
Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes
Chmielecki et al. Cancer Discovery.
Triple Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents
Ganesan et al. Molecular Cancer Therapeutics.
Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy
Ross et al. Mod Pathol.